Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy

Thus far immunotherapy has had limited impact on ovarian cancer. Vigil (a novel DNA-based multifunctional immune-therapeutic) has shown clinical benefit to prolong relapse-free survival (RFS) and overall survival (OS) in the BRCA wild type and HRP populations. We further analyzed molecular signals r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sliheet, Elyssa, Robinson, Molly, Morand, Susan, Choucair, Khalil, Willoughby, David, Stanbery, Laura, Aaron, Phylicia, Bognar, Ernest, Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293751/
https://www.ncbi.nlm.nih.gov/pubmed/34785763
http://dx.doi.org/10.1038/s41417-021-00400-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293751/
https://www.ncbi.nlm.nih.gov/pubmed/34785763
http://dx.doi.org/10.1038/s41417-021-00400-x

Ejemplares similares